{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:29:13Z","timestamp":1786984153579,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ahj.2019.04.009","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T01:36:07Z","timestamp":1556674567000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post\u2013Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)"],"prefix":"10.1016","volume":"213","author":[{"given":"Liza Miriam","family":"Pina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh N.","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Michelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Justino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jefferies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"McCrindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.04.009_bb0005","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","article-title":"Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association","volume":"128","author":"Giglia","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.04.009_bb0010","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jacc.2012.08.1023","article-title":"Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure","volume":"61","author":"McCrindle","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.04.009_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/CIRCULATIONAHA.107.748566","article-title":"Fontan operation after 3 decades: what we have learned","volume":"117","author":"Gersony","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.04.009_bb0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imj.12318","article-title":"The Australia and New Zealand Fontan Registry: description and initial results from the first population-based Fontan registry","volume":"44","author":"Iyengar","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.ahj.2019.04.009_bb0025","author":"The Australian & New Zealand Fontan Registry"},{"key":"10.1016\/j.ahj.2019.04.009_bb0030","series-title":"European Congenital Heart Surgeon Association and Congenital Heart Surgeons' Society 4th joint meeting. Venice, Italy","article-title":"Patterns of treatment and early outcomes in children with functionally single ventricle, ECHSA single ventricle study","author":"Maruszewski","year":"2016"},{"key":"10.1016\/j.ahj.2019.04.009_bb0035","author":"The Society of Thoracic Surgeons"},{"key":"10.1016\/j.ahj.2019.04.009_bb0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0022-5223(98)70310-1","article-title":"Thromboembolic complications after fontan procedures--the role of prophylactic anticoagulation","volume":"115","author":"Monagle","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ahj.2019.04.009_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/pcsu.2002.29716","article-title":"Thromboembolic problems after the Fontan operation","volume":"5","author":"Monagle","year":"2002","journal-title":"Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu"},{"key":"10.1016\/j.ahj.2019.04.009_bb0050","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0022-5223(00)70010-9","article-title":"Intracardiac thrombus formation after the Fontan operation","volume":"119","author":"Balling","year":"2000","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ahj.2019.04.009_bb0055","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/0735-1097(91)90512-8","article-title":"Transesophageal echocardiography detects thrombus formation not identified by transthoracic echocardiography after the fontan operation","volume":"18","author":"Fyfe","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.04.009_bb0060","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/0735-1097(91)90847-3","article-title":"Transesophageal echocardiography in evaluation and management after a Fontan procedure","volume":"17","author":"Stumper","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.04.009_bb0065","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.113.008428","article-title":"Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)\/National Institutes of Health (NIH) working group on thrombosis in pediatric cardiology and congenital heart disease","volume":"130","author":"McCrindle","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.04.009_bb0070","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2011.01.061","article-title":"A multicenter, randomized trial comparing heparin\/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children","volume":"58","author":"Monagle","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.04.009_bb0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00246-010-9808-4","article-title":"Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis","volume":"32","author":"Marrone","year":"2011","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.ahj.2019.04.009_bb0080","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jpeds.2012.03.004","article-title":"Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation","volume":"161","author":"Manlhiot","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.ahj.2019.04.009_bb0085","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1016\/j.ijcard.2013.06.058","article-title":"Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation","volume":"168","author":"Potter","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2019.04.009_bb0090","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/heartjnl-2015-307930","article-title":"Strategies for thromboprophylaxis in Fontan circulation: a meta-analysis","volume":"101","author":"Alsaied","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2019.04.009_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2019.04.009_bb0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MBC.0000000000000033","article-title":"The in-vitro anticoagulant effect of rivaroxaban in neonates","volume":"25","author":"Attard","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.ahj.2019.04.009_bb0105","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.thromres.2012.07.009","article-title":"The in vitro anticoagulant effect of rivaroxaban in children","volume":"130","author":"Attard","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2019.04.009_bb0110","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00246-012-0315-7","article-title":"The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium","volume":"33","author":"Rychik","year":"2012","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.ahj.2019.04.009_bb0115","unstructured":"Schnizler K. PH-38483: physiology-based prediction of rivaroxaban pharmacokinetics in children with congenital heart disease after Fontan procedure. Data on file. 2015."},{"key":"10.1016\/j.ahj.2019.04.009_bb0120","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2019.04.009_bb0125","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.04.009_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.04.009_bb0135","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.04.009_bb0140","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.04.009_bb0145","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.04.009_bb0150","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2019.04.009_bb0155","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/j.1538-7836.2011.04433.x","article-title":"Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children","volume":"9","author":"Mitchell","year":"2011","journal-title":"J Thromb Haemost"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319300973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319300973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:02:58Z","timestamp":1757570578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319300973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":31,"alternative-id":["S0002870319300973"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.04.009","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post\u2013Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}